Vacinação Página 2

ECDC - Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice

European Centre for Disease Prevention and Control

This document outlines the key challenges that countries are facing with the COVID-19 vaccination rollout and lessons learned to mitigate these challenges.

JAMA - SARS-CoV-2 Vaccines

JAMA NETWORKShortly after SARS-CoV emerged at the turn of the 21st century, the spike (S) protein (particularly in its prefusion [native] conformation) was identified as the immunodominant antigen of the virus. Evaluation of patients with...

ECDC - Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update

European Centre for Disease Prevention and ControlSeveral EU/EEA countries have observed a decline in the overall incidence of SARS-CoV-2 in recent weeks, most probably due to the impact of tightened non-pharmaceutical interventions (NPIs).

ECDC - Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA

European Centre for Disease Prevention and ControlOn 19 January 2021 the European Commission set out actions to step up the response against the COVID-19 pandemic and accelerate the rollout of vaccination campaigns across the EU, with the aim to...

ECDC - Integrated COVID-19 response in the vaccination era

European Centre for Disease Prevention and ControlDue to the emergence of more transmissible variants of SARS-CoV-2, it will be necessary to strengthen and maintain response measures in the coming months to avoid further rises in mortality, even...

AMP - Allergic Reactions to COVID-19 Vaccines: An Allergist’s Perspective

Acta Médica PortuguesaThe COVID-19 vaccines approved so far for use in the European Union (EU) include those from Pfizer/BioNTech®, Moderna® and AstraZeneca®. Two severe cases of anaphylaxis that were resolved after treatment were reported on the...

JAMA - Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

JAMA NETWORKOn December 11, 2020, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine, administered as 2 doses separated by 21...

NEJM - Maintaining Safety with SARS-CoV-2 Vaccines

The New England Journal of MedicineTo date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in...

WHO - Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding

World Health OrganizationThe conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of placebo controls and...

WHO - mRNA-1273 vaccine (Moderna) against COVID-19 Background document (draft)

World Health OrganizationThe messenger ribonucleic acid (mRNA) vaccine platform has advantages as a pandemic-response strategy, given its efficiency in immunogen design and manufacturing. As mRNA is a non-infectious, non-integrating platform,...

AMP - COVID-19 Vaccine: From Theory to Practice

Acta Médica PortuguesaDesde o primeiro diagnóstico de COVID-19 em Wuhan, até à data atual, foram infetadas pelo vírus SARS-CoV-2, a nível mundial, mais de 64 milhões de pessoas, causando mais de 1,5 milhões de óbitos.1 Desde que foi reconhecida...

WHO - Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing

World Health Organization

This interim guidance has been developed based on the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its 5 January 2021 extraordinary meeting.

AMP - Influenza Vaccination in Patients with Cardiovascular Disease Under 65 in the COVID-19 Era

Acta Médica Portuguesa

Sabemos que a vacinação contra o vírus influenza nos doentes com patologia cardiovascular reduz significativamente o número de eventos cardiovasculares major e a mortalidade cardiovascular.

NEJM - Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

The New England Journal of MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective...

THE LANCET - Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

The LancetA safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the...